T:slim X2 is First Insulin Pump with Automated Insulin Delivery to Integrate with Freestyle Libre 2


 2024-01-12

On January 8, 2024, Abbott announced that their continuous glucose monitoring (CGM) system, the FreeStyle Libre 2 Plus, can now be fully integrated with the t:slim X2 insulin pump automated insulin delivery (AID) system—the first AID system to integrate with the FreeStyle Libre CGM. 

This is a huge access win for patients, especially existing Libre users who are insulin-dependent. 

What this means for people with diabetes

The integration of the t:slim X2 insulin pump with Control-IQ technology marks the first AID system to integrate with Abbot’s newest CGM system, the FreeStyle Libre 2 Plus. 

For the first time, Libre users in the United States can experience the benefits of a hybrid closed-loop insulin system to help predict and prevent both high and low blood sugar levels

The t:slim X2 insulin pump connects wirelessly with Bluetooth technology to the Libre CGM system, which sends blood sugar level updates every minute to the insulin pump. Users can view their blood sugar level data on either their insulin pump or t:connect, the accompanying mobile app. 

The FreeStyle Libre 2 Plus is Abbott’s newest technology that was specifically approved by the Food and Drug Administration (FDA) for use with AID insulin pump systems in 2023. 

It is the first and only CGM available in the US with a wear time of 15 days for both children and adults. 

“Our FreeStyle Libre portfolio empowers people living with diabetes to have more control over their health and eases the burden of their condition by using a continuous glucose monitoring system with unsurpassed accuracy that is simple, easy and affordable to use,” said Jared Watkin, executive vice president of Abbott’s diabetes care business. “Through the integration of Tandem’s t:slim X2 insulin pump with our FreeStyle Libre 2 Plus sensor, people only need two sensors a month, which ensures both a more convenient and more affordable experience.”

The Control-IQ technology predicts blood sugar levels thirty minutes into the future, automatically adjusting insulin delivery every five minutes based on blood sugar level readings from the CGM. It can also automatically deliver correction boluses of insulin of up to one per hour to prevent high blood sugar levels. 

John Sheridan, president and chief executive officer of Tandem Diabetes Care said in a statement, “Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the United States. This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”

With these two powerful systems integrated, people with diabetes, especially existing Libre users who take insulin, will experience more ease and efficiency with their diabetes management than ever before. 

Availability in the US 

Tandem Diabetes Care will send out instructions via email to all in-warranty t:slim X2 users in the US offering the option to add the new FreeStyle Libre 2 Plus integration at no cost with a remote software update. 

T:slim X2 pumps for new customers will now also be shipped with the updated software pre-loaded into the system.

More information about the software update process for existing in-warranty pump users, including system requirements, is available at tandemdiabetes.com/softwareupdate.

For more information on accessing the t:slim X2 insulin pump and FreeStyle Libre 2 Plus sensor integration, please visit tandemdiabetes.com/products.

This content mentions Freestyle Libre 2, an active partner of Beyond Type 1.

News coverage by the Beyond Type 1 team is operated independently from any content partnerships. Beyond Type 1 maintains full editorial control of all content published on our platforms.